Immunohistochemical study of characteristics of bile duct dysplasia evaluated on the basis of expression of metastasis/invasion-related factors and p53

Journal of Hepato-Biliary-Pancreatic Surgery

Volumn 11, Issue 6, 2004, Pages 409-416

  Chiba, Hideo ^a   Nagai, Hideo ^a   Ohdaira, Takeshi ^a   Yasuda, Yoshikazu ^a   Saito, Ken ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

Bile duct dysplasia; Immunohistochemical study; Intercellular adhesive factors; Matrix metalloproteinases

Indexed keywords

ALPHA CATENIN; BETA CATENIN; BIOLOGICAL FACTOR; CELL ADHESION MOLECULE; GELATINASE A; GELATINASE B; INTERSTITIAL COLLAGENASE; MATRIX METALLOPROTEINASE; PROTEIN P53; TISSUE INHIBITOR OF METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; UVOMORULIN;

ARTICLE; BILE DUCT CANCER; BILE DUCT CARCINOMA; CANCER INVASION; CANCER SURGERY; CARCINOGENESIS; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE SEVERITY; DYSPLASIA; EPITHELIUM; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAXIMUM LIKELIHOOD METHOD; METASTASIS; PHENOTYPE; PROTEIN EXPRESSION; STATISTICAL SIGNIFICANCE;

BILE DUCT NEOPLASMS; BILE DUCTS; CELL ADHESION MOLECULES; HUMANS; IMMUNOHISTOCHEMISTRY; MATRIX METALLOPROTEINASES; NEOPLASM INVASIVENESS; TISSUE INHIBITOR OF METALLOPROTEINASES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 11244270603     PISSN: 09441166     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00534-004-0928-1     Document Type: Article

References (54)

1. Nagakawa T, Kayahara M, Ikeda S, Futakawa S, Kakita A, Kawarada H, Matsuno M, Takada T, Takasaki K, Tanimura H, Tashiro S, Yamaoka Y (2002) Biliary tract cancer treatment: results from the biliary tract cancer statistics registry in Japan. J Hepatobiliary Pancreat Surg 9:569-575
2. Tabata M, Kawarada Y, Yokoi H, Higashiguchi T, Isaji S (2000) Surgical treatment for hilar cholangiocarcinoma. J Hepatobiliary Pancreat Surg 7:148-154
3. Albores-Saavedra J, Henson DE (1986) Tumors of the gallbladder and extrahepatic bile ducts. In: Atlas of tumor pathology, 2nd series, fascicle 22. Armed Forces Institute of Pathology, Washington, DC; pp 44-53
4. Latio M (1983) Carcinoma of extrahepatic bile ducts. A histopathological study. Pathol Res Pract 178:67-72
5. Suzuki M, Takahashi T, Ouchi K, Matsuno S (1989) The development and extension of hepatohilar bile duct carcinoma. A threedimensinal tumor mapping in the intrahepatic biliary tree visualized with the aid of a graphics computer system. Cancer 64:719-726
6. Albores-Saavedra J, Henson DE, Klimstra DS (2000) Tumors of the gallbladder and extrahepatic bile ducts, and ampulla of Vater. In: Atlas of tumor pathology, 3rd series, fascicle 27. Armed Forces Institute of Pathology, Washington, DC; pp 191-215
7. Bae JY, Park YN, Nakamura Y, Lee WJ, Kim JY, Park C (2002) Intestinal type cholangiocarcinoma of intrahepatic large bile duct associated with hepatolithiasis - a new histologic subtype for further investigation. Hepatogastroenterology 49:628-630
8. Shimonishi T, Sasaki M, Nakanuma Y (2000) Precancerous lesions of intrahepatic cholangiocarcinoma. J Hepatobiliary Pancreat Surg 7:542-550
9. Terada T, Nakanuma Y, Ohta T, Nagakawa T (1992) Histological features and interphase nucleolar organizer regions in hyperplasia, dyplasia, and neoplastic epithelium of intrahepatic bile ducts in hepatolithiasis. Histopathology 21:233-240
10. Ajiki T, Onoyama H, Yamamoto M, Asaka K, Fujimori T, Maeda S, Saitoh Y (1996) p53 protein expression and prognosis in gallbladder carcinoma and premalignant lesion. Hepatogastroenterology 43:521-526
11. Bergquist A, Glaumann H, Stal P, Wang G, Broome U (2001) Biliary dysplasia, cell proliferation and nuclear DNAfragmentation in primary sclerosing cholangitis with and without cholangiocarcinoma. J Intern Med 249:69-75
12. Bloem BR, Beckley DJ, van Dijk JG, Zwinderman AH, Roos RA (1992) Are medium and long latency reflexes a screening tool for early Parkinson's disease? J Neurol Sci 113:38-42
13. Vakil N, Affi A, Robinson J, Sundaram M, Phadnis S (2000) Prospective blinded trial of a fecal antigen test for the detection of Helicobacter pylori infection. Am J Gastroenterol 95:1699-1701
14. Pinna GD, La Rovere MT, Maestri R, Mortara A, Bigger JT, Scwartz PJ (2000) Comparison between invasive and non-invasive measurements of baroreflex sensitivity. Eur Heart J 21:1522-1529
15. Frixen UH, Behrens J, Sachs M, Eberle G, Voss B, Warda A, Lochner D, Birchmeier W (1991) E-cadherin-mediated cell-cell adhesion prevents invasiveness of human carcinoma cells. J Cell Biol 113:173-185
16. Frixen UH, Nagamine Y (1993) Stimulation of urokinase-type plasminogen activator expression by blockage of E-cadherindependent cell-cell adhesion. Cancer Res 53:3618-3623
17. Vleminckx K, Vakaet L Jr, Mareel M, Fiers W, van Roy F (1991) Genetic manipulation of E-cadherin expression by epithelial tumor cells reveals an invasion suppressor role. Cell 66:107-119
18. Liotta LA, Rao CN, Barsky SH (1983) Tumor invasion and the extracellular matrix. Lab Invest 49:636-649
19. Liotta LA, Rao CN (1986) Tumor invasion and metastasis. Monogr Pathol 27:183-192
20. Strongin AY, Collier I, Bannikov G, Marmer BL, Grant GA, Goldberg GI (1995) Mechanism of cell surface activation of 72-kDa type IV collagenase. Isolation of the activated form of the membrane metalloprotease. J Biol Chem 270:5331-5338
21. Kinoshita T, Sato H, Okada A, Ohuchi E, Imai K, Okada Y, Seiki M (1998) TIMP-2 promotes activation of progelatinase A by membrane-type 1 matrix metalloproteinase (MT1-MMP) immobilized on agarose beads. J Biol Chem 26:16098-16103
22. Ohuchi E, Imai K, Fujii Y, Sato H, Seki M, Okada Y (1997) Membrane type 1 matrix metalloproteinase digests interstitial collagens and other extracellular matrix macromolecules. J Biol Chem 272:2446-2451
23. d'Ortho MP, Will H, Atkinson S, Butler G, Messent A, Gavrilovic J, Smith B, Timpl R, Zardi L, Murphy G (1997) Membrane-type matrix metalloproteinase 1 and 2 exhibit broad-spectrum proteolytic capacities comparable to many matrix metalloproteinases. Eur J Biochem 250:751-757
24. Bertaux B, Hornebeck W, Eisen AZ, Dubertret L (1991) Growth stimulation of human keratinocytes by tissue inhibitor of metalloproteinase. J Invest Dermatol 97:670-685
25. Hayakawa T, Yamashita K, Tanzawa K, Uchijima E, Iwata K (1992) Growth-promoting activity of tissue inhibitor of metalloproteinase-1 (TIMP-1) for a wide range of cells. FEBS Lett 298:29-32
26. Hayakawa T, Yamashita K, Ohuci E, Shinagawa A (1994) Cell growth-promoting activity of tissue inhibitor of metalloproteinase-2 (TIMP-2). J Cell Sci 107:2373-2379
27. Kikuchi K, Kadono T, Furue M, Tamaki K (1997) Tissue inhibitor of metalloproteinase-1 (TIMP-1) may be an autocrine growth factor in scleroderma fibroblasts. J Invest Dermatol 108:281-284
28. Saika S, Kawashima Y, Okada Y, Tanaka S, Yamanaka O, Ohnishi Y, Ooshima A (1997) Recombinant TIMP-1 and -2 enhance the proliferation of rabbit corneal epithelial cells in vitro and the spreading of rabbit corneal epithelial cells in site. Curr Eye Res 17:47-52
29. Luparello C, Avanzato G, Carella C, Pucciminafra I (1999) Tissue inhibitor of metalloproteinase (TIMP)-1 and proliferative behavior of clonal breast cancer cells. Breast Cancer Res Treat 54:235-244
30. Ozawa M, Baribault H, Kemler R (1989) The cytoplasmic domain of the cell adhesion molecule uvomorulin associates with three independent proteins structurally related in different species. EMBO J 8:1711-1717
31. Kemler R (1993) From cadherins to catenins: Cytoplasmic protein interaction and regulation of cell adhesion. Trends Genet 9:317-321
32. Nathke IS, Hinck L, Swedlow JR, Papkoff J, Nelson WJ (1994) Defining interactions and distributions of cadherin and catenin complexes in polarized epithelial cells. J Cell Biol 125:1341-1352
33. Schipper Jh, Frixen UH, Behrens J, Unger A, Jahnke K, Birchmeier W (1991) E-cadherin expression in squamous cell carcinomas of head and neck: Inverse correlation with tumor dedifferentiation and lymph node metastasis. Cancer Res 51:6328-6337
34. Umbas R, Schalken JA, Aalders TW, Carter BS, Karthaus HF, Schaafsma HE, Debrayne FM, Isaacs WB (1992) Expression of the cellular adhesion molecule E-cadherin is reduced or absent in high-grade prostate cancer. Cancer Res 52:5104-5109
35. Matsui S, Shiozaki H, Inoue M, Tamura S, Doki Y, Kadowaki T, Iwazawa T, Shimaya K, Nagafuchi A, Tsukita S, Mori T (1994) Immunohistochemical evaluation of alpha-catenin expression in human gastric cancer. Virchows Arch 424:375-381
36. Kadowaki T, Shiozaki H, Inoue M, Tamura S, Oka H, Doki Y, Iihara K, Matsui S, Iwazawa T, Nagafuchi A (1994) E-cadherin and alpha-catenin expression in esophageal cancer. Cancer Res 54:291-296
37. Rimm DL, Sinard JH, Morrow JS (1995) Reduced alpha-catenin and E-cadherin expression in breast cancer. Lab Invest 72:506-512
38. Bongiorno PF, al-Kasspooles M, Lee SW, Rachwal WJ, Moore JH, Whyte RI, Orringer MB, Beer DG (1995) E-cadherin expression in primary and metastatic thoracic neoplasms and in Barretts oesophagus. Br J Cancer 71:166-172
39. Shimazui T, Bringuier PP, van Berkel H, Ruijter E, Akaza H, Debruyne FM, Oosterwijk E, Schalken JA (1997) Decreased expression of alpha-catenin is associated with poor prognosis of patients with localized renal cell carcinoma. Int J Cancer 74:523-528
40. Raftopoulos I, Davaris P, Karatzas G, Karayannacos P, Kouraklis G (1998) Level of alpha-catenin expression in colorectal cancer correlates with invasiveness, metastatic potential, and survival. J Surg Oncol 68:92-99
41. Chow V, Yuen AP, Lam KY, Tsao GS, Ho WK, Wei WI (2001) A comparative study of the clinicopathological significance of Ecadherin and catenins (alpha, beta, gamma) expression in the surgical management of oral tongue carcinoma. J Cancer Res Clin Oncol 127:59-63
42. Zhao XJ, Li H, Chen H, Liu YZ, Zhang LH, Liu SX, Feng QL (2003) Expression of e-cadherin and beta-catenin in human esophageal squamous cell carcinoma: Relationships with prognosis. World J Gastroenterol 9:225-232
43. Tan DSP, Potts HW, Leong AC, Gillet CE, Skilton D, Harreis WH, Liebmann RD, Hanby AM (1999) The biological and prognostic significance of cell polarity and E-cadherin in grade I infiltrating ductal carcinoma of the breast. J Pathol 189:20-27
44. Gillet CE, Miles DW, Ryder K, Skilton D, Liebman RD, Spingall RJ, Barnes DM, Hanby AM (2001) Retention of the expression of E-cadherin and catenins is associated with shorter survival in grade III ductal carcinoma of the breast. J Pathol 193:433-441
45. Karayiannakis AJ, Syrigos KN, Polychronidis A, Simopoulos C (2001) Expression pattern of alpha-, beta-, and gamma-catenin in pancreatic cancer: Correlation with E-cadherin expression, pathological features and prognosis. Anticancer Res 21:4127-4134
46. Levine AJ, Momand J, Finlay CA (1991) The p53 tumour suppressor gene. Nature 351:453-456
47. Yokozaki H, Kuniyasu H, Kitadai Y, Nishimura K, Todo H, Ayhan A, Yasui W, Ito H, Tahara E (1992) p53 point mutations in primary human gastric carcinomas. J Cancer Res Clin Oncol 119:67-70
48. Oda T, Tsuda H, Scarpa A, Sakamoto M, Hirohashi S (1992) p53 gene mutation spectrum in hepatocellular carcinoma. Cancer Res 52:6358-6364
49. Sasa M, Kondo K, Komaki K, Uyama T, Morimoto T, Monden Y (1993) Frequency of spontaneous p53 mutation (CpG site) in breast cancer in Japan. Breast Cancer Res Treat 27:247-252
50. Scarpa A, Capelli P, Mukai K, Zamboni G, Oda T, Iacono C, Hirohashi S (1993) Pancreatic adenocarcinomas frequently show p53 gene expressions. Am J Pathol 142:1534-1543
51. Milner BJ, Allan LA, Eccles DM, Kitchener HC, Leonard RC, Kelly KF, Parkin DE, Haites NE (1993) p53 mutation is a common genetic event in ovarian carcinomas. Cancer Res 53:2128-2132
52. Greenblatt MS, Bennett WP, Hollstein M, Harris CC (1994) Mutations in the p53 tumor suppressor gene: Clues to cancer etiology and molecular pathogenesis. Cancer Res 54:4855-4878
53. Takagi S, Naito E, Yamanochi H, Ohtsuka H, Kominami R, Yamamoto M (1994) Mutation of the p53 gene in gallbladder cancer. Tohoku J Exp Med 172:283-289
54. Yu AE, Murphy AN, Stetler-Stevenson WG (1998) 72-kDa Gelatinase (gelatinase A): Structure, activation, regulation, and substrate specificity. In: Parks WC, Mecham RP (eds) Matrix metalloproteinase. Academic, San Diego, pp 85-113